Skip to content
DraconiticResearch
Search Sources API
201,818 studies31 sourcesUpdated 51 min ago
Peer-reviewedCC BYFrontiers in genetics

Deep learning-based genetic disease prediction with Monte Carlo (MC) dropout uncertainty estimation: a comparative study with classical machine learning baselines

  1. 1Department of Computer Science & Engineering, Koneru Lakshmaiah Education Foundation, Vaddeswaram, India.

Abstract

Background: Deep neural networks have been successfully applied to structured clinical data with a good predictive performance, but their point predictions do not reflect an indication of confidence, which limits their trustworthiness in screening for genetic conditions where an overconfident misclassification may delay the appropriate confirmatory testing or intervention. Methods: A feed-forward neural network (128-64-32 hidden units, batch normalization, and dropout p = 0.3) was trained to classify patients into five genetic-disease-associated groups based on twelve regularly accessible clinical and molecular biomarkers, using a publicly available, pre-labelled structured biomedical dataset (n = 1,000) whose real-world clinical vs. synthetic provenance could not be independently confirmed (see Section 2.1 and Limitations). Performance was assessed using stratified 5-fold cross-validation versus four traditional baselines (logistic regression, random forest, SVM, gradient boosting; McNemar’s test for pairwise significance). We quantified predictive uncertainty using Monte Carlo (MC) Dropout (T up to 200 stochastic passes), decomposed it into epistemic and aleatoric components, and evaluated it thru calibration analysis (ECE, MCE, Brier score, negative log-likelihood), an uncertainty-quality analysis (low/medium/high uncertainty strata), a selective-prediction (risk-coverage) analysis, a seven-configuration ablation study, and robustness testing across random seeds, reduced training data, and Gaussian feature noise. Results The developed network achieved 94.30% +- 1.36% cross-validated accuracy which was statistically comparable to logistic regression (p = 0.092) and gradient boosting (p = 0.238) but considerably inferior to random forest (95.50% +- 1.26%, p = 0.0018) and SVM (95.30% +- 1.36%, p = 0.0063). MC-Dropout obtained 93.33% accuracy (macro F1 = 0.933, macro ROC-AUC = 0.971, MCC = 0.917) with ECE = 0.076 on a held-out test partition—numerically the highest (worst) ECE among the six model/inference configurations evaluated, exceeding all four classical baselines (ECE 0.024–0.066), although MC-Dropout inference reduced negative log-likelihood substantially relative to deterministic inference (0.370 vs. 0.445), indicating its calibration benefit is concentrated in reducing the penalty for confident errors rather than in bin-wise confidence-accuracy alignment. Errors were about twice as likely in the highest (most uncertain) tercile of predictions than in the lowest (12.0% vs. 6.0% mistake rate), and 60% of all misclassifications were within the high-uncertainty group. Removing the most doubtful 20%–30% of predictions yielded a retained-sample accuracy of above 95%. Accuracy and calibration were consistent across five random seeds (93.07%) and deteriorated gracefully with increasing predictive entropy under synthetic feature-noise perturbation. Conclusion: On this structured, moderate-sized genetic-disease benchmark dataset—evaluated entirely through internal computational validation, without external or prospective clinical testing—classical machine learning algorithms achieved statistically comparable or slightly higher raw classification accuracy than this deep learning approach under standard, non-tuned hyperparameters for all models.

Related

  1. A comparative analysis of graph neural networks and classical machine learning for carbapenem-resistance prediction and genomic interpretation in Acinetobacter baumannii
    Irfan Sharif Shaik, Morteza Sarmadi
    Frontiers in bioinformaticsPeer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMC
  2. BioGraphBench-PPI enables audit-first evaluation of negative-sampling contracts and structural baselines in protein interaction networks
    Alejandro Cabrera-Andrade, Jorge Robalino-Díaz, Iván Dueñas-Espín +2
    Frontiers in bioinformaticsPeer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMC
  3. Deep learning perturbation models can outperform baselines on calibrated metrics
    Henry E. Miller, Gabriel Mejia, Francis Leblanc +3
    Nature BiotechnologyPeer-reviewedCC BYFull text18 citedMolecular biology & gene regulationOpenAlex
  4. Distinct host genetic determinants of HIV acquisition and disease progression: the case of classical HLA class I
    Marion Amujal, James Bumba
    Frontiers in geneticsPeer-reviewedCC BYFull textGeneral biochemistryEurope PMC
  5. Structure-Preserving Excess Gibbs Learning for Multicomponent Phase Equilibria: A Falsifiable and Uncertainty-Aware Synthetic Study
    Pedro Robles, Luis Rios-Colque, Vanesa Bazan +1
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0Full textGeneral biochemistryCrossrefEurope PMC
BibTeX
@article{keerthana2026deep,
  title = {{Deep learning-based genetic disease prediction with Monte Carlo (MC) dropout uncertainty estimation: a comparative study with classical machine learning baselines}},
  author = {V S Keerthana and Tarak Hussain},
  journal = {Frontiers in genetics},
  year = {2026},
  month = oct,
  doi = {10.3389/fgene.2026.1969295},
  url = {https://europepmc.org/article/PMC/PMC13724469},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Deep learning-based genetic disease prediction with Monte Carlo (MC) dropout uncertainty estimation: a comparative study with classical machine learning baselines
AU  - V S Keerthana
AU  - Tarak Hussain
PY  - 2026
DA  - 2026/10/19
JO  - Frontiers in genetics
DO  - 10.3389/fgene.2026.1969295
UR  - https://europepmc.org/article/PMC/PMC13724469
AB  - Background: Deep neural networks have been successfully applied to structured clinical data with a good predictive performance, but their point predictions do not reflect an indication of confidence, which limits their trustworthiness in screening for genetic conditions where an overconfident misclassification may delay the appropriate confirmatory testing or intervention. Methods: A feed-forward neural network (128-64-32 hidden units, batch normalization, and dropout p = 0.3) was trained to classify patients into five genetic-disease-associated groups based on twelve regularly accessible clinical and molecular biomarkers, using a publicly available, pre-labelled structured biomedical dataset (n = 1,000) whose real-world clinical vs. synthetic provenance could not be independently confirmed (see Section 2.1 and Limitations). Performance was assessed using stratified 5-fold cross-validation versus four traditional baselines (logistic regression, random forest, SVM, gradient boosting; McNemar’s test for pairwise significance). We quantified predictive uncertainty using Monte Carlo (MC) Dropout (T up to 200 stochastic passes), decomposed it into epistemic and aleatoric components, and evaluated it thru calibration analysis (ECE, MCE, Brier score, negative log-likelihood), an uncertainty-quality analysis (low/medium/high uncertainty strata), a selective-prediction (risk-coverage) analysis, a seven-configuration ablation study, and robustness testing across random seeds, reduced training data, and Gaussian feature noise. Results The developed network achieved 94.30% +- 1.36% cross-validated accuracy which was statistically comparable to logistic regression (p = 0.092) and gradient boosting (p = 0.238) but considerably inferior to random forest (95.50% +- 1.26%, p = 0.0018) and SVM (95.30% +- 1.36%, p = 0.0063). MC-Dropout obtained 93.33% accuracy (macro F1 = 0.933, macro ROC-AUC = 0.971, MCC = 0.917) with ECE = 0.076 on a held-out test partition—numerically the highest (worst) ECE among the six model/inference configurations evaluated, exceeding all four classical baselines (ECE 0.024–0.066), although MC-Dropout inference reduced negative log-likelihood substantially relative to deterministic inference (0.370 vs. 0.445), indicating its calibration benefit is concentrated in reducing the penalty for confident errors rather than in bin-wise confidence-accuracy alignment. Errors were about twice as likely in the highest (most uncertain) tercile of predictions than in the lowest (12.0% vs. 6.0% mistake rate), and 60% of all misclassifications were within the high-uncertainty group. Removing the most doubtful 20%–30% of predictions yielded a retained-sample accuracy of above 95%. Accuracy and calibration were consistent across five random seeds (93.07%) and deteriorated gracefully with increasing predictive entropy under synthetic feature-noise perturbation. Conclusion: On this structured, moderate-sized genetic-disease benchmark dataset—evaluated entirely through internal computational validation, without external or prospective clinical testing—classical machine learning algorithms achieved statistically comparable or slightly higher raw classification accuracy than this deep learning approach under standard, non-tuned hyperparameters for all models.
SN  - 1664-8021
ER  -